Intensity Therapeutics Inc. (NASDAQ:INTS) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have been assigned an average recommendation of “Moderate Buy” from the four research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $37.50.

A number of analysts recently weighed in on INTS shares. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, April 4th. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Weiss Ratings cut shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, April 24th. Finally, Freedom Capital raised shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, March 30th.

Intensity Therapeutics Stock Down 4.7%

Shares of NASDAQ:INTS opened at $4.46 on Thursday. The stock has a market capitalization of $12.04 million, a price-to-earnings ratio of -0.78 and a beta of 2.94. Intensity Therapeutics has a 1-year low of $4.46 and a 1-year high of $43.50. The company’s fifty day moving average is $5.35 and its two-hundred day moving average is $8.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.86 and a current ratio of 4.86.

Intensity Therapeutics (NASDAQ:INTS) last issued its earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.08) by $0.12. Equities analysts anticipate that Intensity Therapeutics will post -2.7 EPS for the current year.

Institutional Trading of Intensity Therapeutics

Large investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in Intensity Therapeutics by 77.8% in the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its position in Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after buying an additional 51,000 shares in the last quarter. Legacy Advisors LLC bought a new position in Intensity Therapeutics in the 4th quarter valued at about $63,000. State Street Corp grew its position in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new position in Intensity Therapeutics in the 4th quarter valued at about $41,000. Institutional investors and hedge funds own 3.74% of the company’s stock.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.